CER Daily Newsfeed

Video: Understanding the Relationship Between Government Policies, Patient Access: John M. O'Brien, PharmD, MPH

(5/2, Julia Bonavitacola, Christina Mattina, John Michael O’Brien, PharmD, MPH, The American Journal of Managed Care) “John Michael O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council (NPC), discussed how continued communication across sectors is vital in helping to understand the relationship between patient access to treatment and government policy.” View Video

ISPOR 2025: Exploring Sessions on Health Technology Assessment

(5/1, The Evidence Base) reports “...Bringing Us Together or Pushing Us Apart: Will JCA, HEMA, and Other Cross-Border Collaboration Initiatives Improve Patient Access?...Speakers: Michael Drummond (University of York), Eldon Spackman (O'Brien Institute for Public Health, University of Calgary), Jon Campbell (National Pharmaceutical Council). With the EU HTAR now in force, coordinated HTA is entering a new era. This session will explore how cross-border initiatives, such as JCA, Joint Nordic HTA Bodies (JNHB) from Denmark, Finland, Iceland, Norway, and Sweden (formerly the FINOSE collaboration), and the Health Economics Methods Advisory (HEMA), are shaping global collaboration, improving efficiency, and potentially accelerating patient access.” Full

Video: Real-World Data, Real-Time Decisions: AI at the Frontlines of Oncology

(5/2, Ravi Parikh, MD, MPP, FACP, Alana Hippensteele, Pharmacy Times) “Ravi Parikh, MD, MPP, FACP, discusses how artificial intelligence is transforming oncology pharmacy by accelerating drug development, enhancing clinical decision-making, supporting value-based care, and raising critical questions about ethics, regulation, and data integrity.” View Video

New Analysis: Fewer Treatments and Cures Under the IRA's Pill Penalty

(5/1, Brianna Allen, PhRMA) comments “...The pill penalty, which allows the government to set the price of pills and other small molecule treatments years before other drugs, is already driving investors away from funding the early development of these vital medicines, according to a report by health consulting firm Vital Transformation. The report, which was published in the Journal Therapeutic Innovation and Regulatory Science, analyzed the impact of the IRA on investment in drug development since the law's introduction in 2021.” Full

Republicans for Price Controls

(5/1, Kimberley A. Strassel, The Wall Street Journal) comments “...But tackling the problem by taking it out on the innovators-by importing other countries' backward policies-will only harm the world's greatest producer of cures and replicate those countries' failing systems. Europe's price controls have reduced its once-thriving pharmaceutical industry to dust, while Europeans (and Australians and Canadians) have access to far fewer new drugs than are available to Americans, including breakthrough cancer treatments. Those nations also show how a lack of innovation leads to even higher healthcare costs in the longer run.” Subscription Required